During the last session, BioNexus Gene Lab Corp (NASDAQ:BGLC)’s traded shares were 0.33 million, with the beta value of the company hitting 1.81. At the end of the trading day, the stock’s price was $5.09, reflecting an intraday loss of -15.73% or -$0.95. The 52-week high for the BGLC share is $15.60, that puts it down -206.48 from that peak though still a striking 60.51% gain since the share price plummeted to a 52-week low of $2.01. The company’s market capitalization is $9.14M, and the average intraday trading volume over the past 10 days was 5.56 million shares, and the average trade volume was 1.48 million shares over the past three months.
BioNexus Gene Lab Corp (NASDAQ:BGLC) trade information
BioNexus Gene Lab Corp (BGLC) registered a -15.73% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -15.73% in intraday trading to $5.09, hitting a weekly high. The stock’s 5-day price performance is -20.84%, and it has moved by 62.10% in 30 days. Based on these gigs, the overall price performance for the year is 81.98%. The short interest in BioNexus Gene Lab Corp (NASDAQ:BGLC) is 15897.0 shares and it means that shorts have 0.13 day(s) to cover.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -21.27%.
BGLC Dividends
BioNexus Gene Lab Corp is due to release its next quarterly earnings in August. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
BioNexus Gene Lab Corp (NASDAQ:BGLC)’s Major holders
BioNexus Gene Lab Corp insiders own 51.11% of total outstanding shares while institutional holders control 0.88%, with the float percentage being 1.80%.
Also, the Mutual Funds coming in first place with the largest holdings of BioNexus Gene Lab Corp (BGLC) shares are Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund and Blackstone Alternative Investment Fd.s-Blackstone Alternative Multi-St . Data provided on May 31, 2025 indicates that Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund owns about 2.37 shares. This amounts to just over 0.13 percent of the company’s overall shares, with a $12053.0 market value. The same data shows that the other fund manager holds slightly less at 3.0, or about 0.00% of the stock, which is worth about $15.0.
